Bayer Science & Education Foundation launches new round of funding

BayerApplications for the Bayer Science & Education Foundation's international scholarship programs are now being accepted for this year's round. In the academic sector, ambitious students can apply for an Otto Bayer, Carl Duisberg, Jeff Schell, or Kurt Hansen scholarship if they are aiming to undertake a study project abroad or from foreign countries planning a project in Germany. The subjects funded include all fields of study related to life sciences, chemistry or medicine as agricultural engineering, biology, biochemistry, plant-/biotechnology, bio / chemical process engineering, human and veterinary medicine, pharmacy, computational life sciences and teacher training in biology or chemistry.

The Bayer Science & Education Foundation's program offers this year again an extra budget of EUR 50,000 for students from African countries who are planning study projects on the scientific topics above in Germany. In addition to the scholarships in the academic sector, the Hermann Strenger scholarships are available to support young people on a non-academic training program looking to gain initial work experience abroad. Applications are invited from committed trainees in commercial, industrial, scientific or medical occupations as well as young professionals in these fields who have completed their training within the past two years. With this program, the Bayer Science & Education Foundation is looking to offer targeted funding to young people in the non-academic sector, enabling them to gain professional experience abroad.

The application deadline for all five scholarship programs is July 18, 2016. Application forms are available online at http://www.bayer-foundations.com. An independent scientific committee will award funding in mid September 2016.

Application forms and further information on the Bayer Fellowship Program and the Bayer Science & Education Foundation are available at http://www.bayer-foundations.com.

Bayer: Science For A Better Life
Bayer is a global enterprise with core competencies in the Life Science fields of health care and agriculture. Its products and services are designed to benefit people and improve their quality of life. At the same time, the Group aims to create value through innovation, growth and high earning power. Bayer is committed to the principles of sustainable development and to its social and ethical responsibilities as a corporate citizen. In fiscal 2015, the Group employed around 117,000 people and had sales of EUR 46.3 billion. Capital expenditures amounted to EUR 2.6 billion, R&D expenses to EUR 4.3 billion. These figures include those for the high-tech polymers business, which was floated on the stock market as an independent company named Covestro on October 6, 2015.

Most Popular Now

Forxiga receives positive EU CHMP opinion for the …

The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended a new indication for the marketing authorisation of Forxi...

US FDA grants Breakthrough Therapy Designation for…

AstraZeneca and its global biologics research and development arm, MedImmune, today announced that the US Food and Drug Administration (FDA) has granted Breakthrough Ther...

New pill can deliver insulin

An MIT-led research team has developed a drug capsule that could be used to deliver oral doses of insulin, potentially replacing the injections that people with type 2 di...

Merck to expand US biopharmaceutical R&D facil…

Merck, a leading science and technology company, today announced a $70 million investment to expand its state of the art research and development (R&D) facility in Biller...

Pfizer receives positive CHMP opinion for Vizimpro…

Pfizer today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending V...

Cannabinoid compounds may inhibit growth of colon …

Medical marijuana has gained attention in recent years for its potential to relieve pain and short-term anxiety and depression. Now, Penn State College of Medicine resear...

Merck Granted U.S. Patent for novel combination of…

Merck, a leading science and technology company, today announced that it has been granted Patent No. US 10,193,695 by the United States Patent and Trademark Office (USPTO...

Simple drug combination creates new neurons from n…

A simple drug cocktail that converts cells neighboring damaged neurons into functional new neurons could potentially be used to treat stroke, Alzheimer's disease, and bra...

The Union for International Cancer Control and Pfi…

In conjunction with World Cancer Day, the Union for International Cancer Control (UICC) and Pfizer Inc. announce the third round of the Seeding Progress And Resources for...

Pfizer and Lilly announce top-line results from se…

Pfizer Inc. (NYSE:PFE) and Eli Lilly and Company (NYSE:LLY) today announced positive top-line results from a Phase 3 study evaluating tanezumab 2.5 mg or 5 mg in patients...

Merck and Tencent announce collaboration on intell…

Merck, a leading science and technology company, signed a strategic collaboration agreement with Tencent, a leading provider of Internet value added services. The collabo...

New insight into cell receptors opens the way for …

New research on how cancer mutations influence a certain type of receptor on the cell membrane opens the way for the development of tailored drugs for certain cancers, su...